首页 | 本学科首页   官方微博 | 高级检索  
     


A randomized,double-blind,placebo controlled,phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy
Authors:Linong Ji MD  Jinmiao Lu PhD  Leili Gao MD  Xiaoguang Yan MD  Jifang Li MM  Zhifeng Cheng MD  Lili Zhang MD  Junhang Tian MM  Ping Li MM  Jie Bai MM  Daosheng Xie MS  Jiahong Zhao MD  Juping Ding MS  Qiang Yu PhD  Tong Wang PhD
Affiliation:1. Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China;2. CGeneTech (Suzhou, China) Co., Ltd, Suzhou, China;3. The First Hospital of Qiqihar, Qiqihar, China;4. Puyang Oilfield general Hospital, Puyang, China;5. The Fourth Hospital of Medical University, Harbin, China;6. Overview of Shijiazhuang Second Hospital, Shijiazhuang, China;7. Luoyang Third People's Hospital, Luoyang, China;8. Yuncheng Central Hospital, Yuncheng, China;9. Liaocheng People's Hospital, Liaocheng, China;10. Beijing noahpharm Medical Technology Co., Ltd, Beijing, China
Abstract:
Keywords:cetagliptin  dipeptidyl peptidase-4 inhibitor  DPP-4  metformin  T2D  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号